Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas
- 1 February 2008
- Vol. 112 (5), 1139-1146
- https://doi.org/10.1002/cncr.23167
Abstract
BACKGROUND. The prognosis for patients with recurrent high‐grade gliomas is poor and treatment options are limited. Current chemotherapeutic regimens can improve clinical outcomes, but extend survival by only a few months. Temozolomide is a methylating agent that is typically administered once daily. Because preclinical studies suggested that a twice‐daily dosing schedule might be more effective, the safety and efficacy of twice‐daily dosing of temozolomide were studied in patients with recurrent gliomas at their first, second, or third recurrence. METHODS. This multi‐institutional trial enrolled 120 patients with recurrent glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligodendroglioma (AO). An initial oral dose of 200 mg/m2 of temozolomide was followed by 9 consecutive doses of 90‐mg/m2 every 12 hours. Treatment cycles were repeated every 28 days. Doses were escalated to 100 mg/m2 twice daily in the absence of unacceptable toxicity or were reduced if unacceptable toxicity occurred. RESULTS. For GBM, AA, and AO patients, respectively, the median progression‐free survival (PFS) was 4.2 months, 5.8 months, and 7.7 months, whereas the median overall survival (OS) was 8.8 months, 14.6 months, and 18 months. The overall response rate (partial and complete) for the GBM, AA, and AO patients was 31%, 46%, and 46%, respectively. Grade 3/4 toxicities included neutropenia (1.1%), thrombocytopenia (3.6%), and anemia (0.3%) (graded according to the World Health Organization grading system). CONCLUSIONS. Twice‐daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity. This regimen compares favorably with other dosing schedules of temozolomide reported in the literature. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 19 references indexed in Scilit:
- One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastomaNeurology, 2004
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- A phase II study of extended low-dose temozolomide in recurrent malignant gliomasNeuro-Oncology, 2002
- An Australian experience with temozolomide for the treatment of recurrent high grade gliomasJournal of Clinical Neuroscience, 2001
- Extended temozolomine (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AGAT)European Journal of Cancer, 2001
- O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II studyInternational Journal of Cancer, 2000
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal of Cancer, 1996
- The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapyJournal of Neurosurgery, 1992